Sagimet Closes $115 Million Financing Round to Fund Phase 3 Acne Trial and Metabolic Disease Programs
Sagimet Biosciences completed a $115 million capital raise led by Commodore Capital and supported by multiple institutional investors to advance its clinical pipeline targeting metabolic and fibrotic diseases. Proceeds will fund a Phase 3 trial of denifanstat for acne treatment, advancement of additional candidates including TVB-3567 and a topical FASN inhibitor program toward IND-enabling studies. The financing enables the company to pursue commercialization activities and expand its therapeutic portfolio addressing areas of significant medical need.
Sagimet's $115 million raise represents a significant capital injection for the company's pipeline of metabolic disease treatments. The funding supports advancement of denifanstat toward late-stage testing for acne, alongside development of TVB-3567 and a topical formulation targeting fatty acid synthase. The investor consortium includes established healthcare-focused venture and asset management firms, signaling confidence in Sagimet's scientific approach to addressing conditions linked to palmitate overproduction.
The financing could accelerate development timelines for treatments targeting metabolic dysfunction and fibrotic disease—areas affecting millions globally. If clinical trials prove successful, denifanstat and companion candidates may expand therapeutic options for patients with acne and metabolic-associated diseases. The capital raise may also influence competitive dynamics in the FASN inhibitor space, potentially driving broader research investment in lipid metabolism as a drug development target across the industry.